此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

2026年6月19日 更新者:LucasBio

A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after anticancer therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The main questions it aims to answer are:

  • What is the maximum tolerated dose of LB-DTK-MV based on dose-limiting toxicity?
  • Does the number of CMV, BKV, or EBV virus viral load decrease within 7 or 14 days after the second infusion of LB-DTK-MV?
  • Do treatment emergent adverse events occur after the second infusion?

Participants will:

  • Receive a single intravenous infusion of LB-DTK-MV during the baseline visit (low dose: 1x10^7/m^2; high dose: 2x10^7/m^2).
  • Receive the second infusion of LB-DTK-MV intravenously at the same dose 14 days after the first infusion.
  • Attend weekly follow-up visits at the clinic for 6 months after the first dose.

研究概览

研究类型

介入性

注册 (估计的)

27

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Nayoun Kim, Ph.D.
  • 电话号码:+82 1040222340
  • 邮箱:nkim@lucasbio.com

学习地点

      • Seoul、韩国、06591
        • 招聘中
        • The Catholic University of Korea Seoul ST.MARY'S Hospital
        • 首席研究员:
          • Dong-Gun Lee, MD-PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Patients aged 19 years or older who have undergone myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplantation using bone marrow, single or double umbilical cord blood, or peripheral blood stem cells (PBSCs). Or patients who have undergone any of the following anticancer treatments:

    • CAR-T: Kymriah, Yescarta
    • Bispecific Antibody: Glofitamab, Mosunetuzumab, Teclistamab, Elranatamab, etc
  2. Patients diagnosed with single or multiple, antiviral-resistant CMV, BKV, and/or EBV despite receiving standard treatment.
  3. Patients who are able to reduce their steroid dosage to 0.5mg/kg/day of Prednisolone (or an equivalent dose) or less.
  4. Patients with a hemoglobin level ≥8.0g/dL.
  5. Patients with evidence of neutrophil engraftment, defined as an absolute neutrophil count (ANC) maintained at 0.5x10^3/μL or higher for 3 consecutive days following allogeneic hematopoietic stem cell transplantation.
  6. Patients with peripheral oxygen saturation (SpO2) ≥90% on room air.
  7. Patients who have at least one MHC class I HLA allele that matches the investigational product.
  8. For women of childbearing potential, those who tested negative on a pregnancy test (blood test) performed on the screening visit.
  9. Female subjects or male subjects with female partners who agree to use the following contraceptive methods during the duration of this clinical trial and who meet the following criteria:

    • Female participants or male participants with female partners who are postmenopausal (diagnosed with non-therapy-induced amenorrhea for 12 months or more or menopause)
    • Female subjects or the female partners of male subjects who are surgically sterile (i.e., lacking ovaries and/or a uterus)
    • Individuals who have agreed to strict abstinence during the clinical trial period [For female participants, intermittent abstinence (e.g., withdrawal during ovulation, the basal body temperature method, or withdrawal after ovulation) does not constitute agreement to abstinence]
    • If the female subject or the female partner of a male subject is a woman of childbearing potential (WOCBP) who has not undergone sterilization, those who meet the following criteria:

      • Hormonal contraceptives (implant, patch, oral)
      • Intrauterine devices
      • Dual barrier method (simultaneous use of the following two contraceptive methods: male condoms, female condoms, cervical caps, contraceptive diaphragms, contraceptive sponges)
  10. Individuals who have voluntarily decided to participate in this clinical trial and have provided written consent to comply with the restrictions.
  11. Individuals deemed suitable as trial subjects through screening tests (vital signs, physical examination, medical and surgical history, electrocardiogram, laboratory tests, etc.).

Exclusion Criteria:

  1. Individuals who have received treatment with ATG (Antithymocyte Globulin), Campath (Alemtuzumab), or other T-cell immunosuppressive monoclonal antibodies within 28 days prior to the first dose.
  2. Individuals who meet any of the following criteria at the time of screening:

    • Uncontrolled hypertension

      • Systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite taking antihypertensive medication.
    • Uncontrolled diabetes: Severe diabetes is defined as follows:

      • Severe hyperglycemia with HbA1C ≥ 10.0%
      • Individuals who have been hospitalized for diabetic ketoacidosis within the past 12 weeks.
      • Individuals who have received emergency treatment or been hospitalized within the past 12 weeks for severe hypoglycemia (glucose <54 mg/dL) accompanied by seizures and loss of consciousness.
    • Other viral infections [Ex. Human Immunodeficiency Virus(HIV), Hepatitis B Virus(HBV), Hepatitis C Virus(HCV)]. However, patients who are tested negative for HBsAg and positive for anti-HBcAb are not subject to this exclusion criterion.
    • Tuberculosis
    • Syphilis
    • Moderate or severe liver damage [Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN)]
    • Chronic kidney disease [eGFR < 30mL/min/1.73m^2]
    • Patients with other uncontrolled infections. However, the following cases are considered controlled infections and do not meet the exclusion criteria:

      • Bacterial infection. Patients must be undergoing definitive antibiotic treatment for the infection and must have shown no signs of progression of the infection for 72 hours prior to enrollment in this clinical trial.
      • Fungal infection. The patient must be receiving systemic antifungal therapy and must have shown no signs of infection progression for 1 week prior to enrollment in this clinical trial.
  3. Patients who have undergone allogeneic hematopoietic stem cell transplantation within 28 days prior to the scheduled first dose, or who have received donor lymphocyte infusion (DLI) within 28 days prior to enrollment in this clinical trial.
  4. Patients with active acute graft-versus-host disease (GvHD) of grade 2 or higher.
  5. Patients requiring urgent anticancer therapy due to rapid tumor progression.
  6. Patients with a history of substance abuse within 24 weeks prior to administration of the investigational drug, or patients suspected of taking drugs of concern based on medical history and physical examination.
  7. Patients requiring vasopressors.
  8. Patients who have previously shown hypersensitivity to T-cell therapy.
  9. Patients with a history of autoimmune disease.
  10. Patients with hemophilia who are at risk of severe bleeding during administration, or patients receiving anticoagulants.
  11. Patients who have received another virus-specific T cell product within 28 days prior to administration of the investigational drug.
  12. Patients with a life expectancy of less than 24 hours at the time of the screening visit.
  13. Patients aged under 19.
  14. Patients deemed ineligible for participation in this clinical trial by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental Group (All)
LB-DTK-MV is an allogeneic cell therapy product derived from a third-party donor and is supplied as a pale-yellow cell suspension at a final concentration of 4x10^7cells/2mL in a colorless, transparent freeze-dried vial. The product is stored frozen until thawed into liquid before administration. Study participants will receive a single intravenous infusion of the assigned cell dose (low dose: 1x10^7/m^2;high dose: 2x10^7/m^2) of LB-DTK-MV on Visit 2 and 14 days after the initial dose.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
CMV viral load
大体时间:From enrollment through 24 weeks after treatment initiation
CMV viral load testing is performed using RT-PCR on blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks.
From enrollment through 24 weeks after treatment initiation
BKV viral load
大体时间:From enrollment through 24 weeks after treatment initiation.
BKV viral load testing is performed using RT-PCR on urine and blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks.
From enrollment through 24 weeks after treatment initiation.
EBV viral load
大体时间:From enrollment through 24 weeks after treatment initiation.
EBV load testing is performed using RT-PCR on blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks.
From enrollment through 24 weeks after treatment initiation.
Immunogenicity Testing
大体时间:From enrollment through 24 weeks after treatment initiation.
Immunogenicity testing using the IFN-γ ELISpot assay is performed weekly for the first 4 weeks following administration of the investigational drug. Thereafter, to evaluate the persistence and reconstitution of the immune response, measurements are taken twice at 2-week intervals, once at 4-week intervals, and once at 12-week intervals. Flow cytometry will be performed concurrently at each time point to evaluate cytokine profiles and immune cell subsets.
From enrollment through 24 weeks after treatment initiation.
Adverse Events
大体时间:From the baseline visit through 24 weeks after treatment initiation.
The investigator must confirm the occurrence of adverse events through medical examinations, including interviews and medical history reviews, during regular visits throughout the clinical trial period. Adverse events shall be assessed at each visit starting from the administration of the investigational drug at the baseline visit (Visit 2); however, from the baseline visit (Visit 2) until the discharge date, adverse events shall be assessed daily, and after the discharge date, assessments shall be conducted according to the procedures for each visit; diseases or symptoms that occurred prior to the first administration of the investigational drug shall be collected as part of the medical history.
From the baseline visit through 24 weeks after treatment initiation.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Dong-Gun Lee, MD-PhD、Department of Infectious Disease, The Catholic University of Korea Seoul St.Mary's Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月4日

初级完成 (估计的)

2027年6月4日

研究完成 (估计的)

2027年6月4日

研究注册日期

首次提交

2026年6月17日

首先提交符合 QC 标准的

2026年6月19日

首次发布 (实际的)

2026年6月26日

研究记录更新

最后更新发布 (实际的)

2026年6月26日

上次提交的符合 QC 标准的更新

2026年6月19日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅